Introduction
T cell Ig domain and mucin domain (TIM) proteins constitute a family of costimulatory molecules that play an important role in effector differentiation of CD4 + cells (1) . The 8 murine and 3 human genes encoding the TIM family are clustered in a chromosomal region (5q32.2 in humans and 11B1.1 in mice) closely associated with autoimmune disease. For example, TIM domain protein 1 (TIM-1) polymorphisms are associated with susceptibility to human asthma, eczema, and rheumatoid arthritis (2, 3) . TIM-1 is expressed on activated CD4 + cells and Th2 cells after polarization in vitro (4) . TIM-4 is a putative TIM-1 ligand; however, these phosphatidylserine receptors may interact indirectly through an exosome bridge (5, 6) . The role of TIM-1 has previously been studied using anti-TIM-1 mAbs. For example, TIM-1 ligation with a high-affinity mAb, 3B3, promotes expansion of antigen-specific T cells expressing Th1 and Th17 cytokines while inhibiting Tregs (4, 7, 8) . Concordantly, 3B3 treatment exacerbates EAE (7) and prevents allograft tolerance mediated by anti-CD154 (8) . In contrast, a lower-affinity anti-TIM-1 mAb, RMT1-10, inhibits EAE (7) and, when combined with rapamycin, induces long-term allograft acceptance in mice (9) . Prolonged engraftment by RMT1-10 is dependent on Th2-cytokine skewing and Treg activity (9) . Thus, TIM-1 is a potent regulator of T cell effector responses in both auto- and alloimmunity.
In addition to humoral immunity, B cells play an increasingly recognized role in shaping T effector cell responses through antigen presentation, costimulation, and cytokine production (10) . For example, in both humans and mice, B cell deficiency or depletion can ameliorate autoimmune diseases primarily mediated by T cells, including type 1 diabetes and rheumatoid and collagen-induced arthritis (11) (12) (13) . However, in various other murine models, such as EAE, inflammatory bowel disease, and contact hypersensitivity, B cell deficiency or depletion worsens disease (14) (15) (16) (17) (18) , which suggests that B cells can also exhibit immunomodulatory function. Indeed, subpopulations of splenic B cells from naive or autoimmune mice can inhibit inflammation in an IL-10-dependent manner (10, (19) (20) (21) . However, definitive identification has been challenging because such regulatory B cells (Bregs) are rare, lack a specific marker, and express detectable IL-10 only upon ex vivo stimulation.
Various Breg phenotypes have been described. For example, Bregs have been detected within splenic marginal zone (MZ) populations (22) (23) (24) or less-mature transitional 2-MZ precursor (T2-MZ) populations (18, 25) . Some studies suggest that Bregs may also reside within the much larger follicular (FO) B cell subset (23, 25, 26) . Recently, Yanaba et al. identified a small subset (~2%) of splenic B cells expressing a CD1d hi CD5 + phenotype that partially overlaps with that of MZ, T2-MZ, and B1 B cells (15) . CD1d hi CD5 + B cells are more enriched for IL-10-producing cells (9%-15%) than other B cell subsets, and it was suggested that they might account for most Breg activity observed in spleen. However, most IL-10 + B cells fall outside of the CD1d hi CD5 + population. A marker that can identify the majority of IL-10 + B cells is critical for improved understanding of Breg biology, including the relationships among Bregs exhibiting different phenotypes.
In the present study we showed that in vivo, TIM-1 was predominantly expressed on B cells, both constitutively and after activation. Surprisingly, the tolerogenic effects of RMT1-10 were completely dependent on TIM-1 + B cells. TIM-1 identified a large majority of B cells capable of IL-4 and IL-10 expression regardless of other markers. Finally, TIM-1 + Bregs were induced by TIM-1 ligation and could transfer long-term acceptance of islet allografts to otherwise-untreated recipients in an IL-10-dependent fashion and could also inhibit allergic airway disease.
Results

B lymphocytes express high levels of TIM-1 compared with T cells. Previ-
ous reports have demonstrated that TIM-1 is expressed by activated T cells, in particular by polarized Th2 cells, in vitro (4) . However, in vivo, we found that less than 2% of splenic CD4 + or CD8 + T cells expressed TIM-1, even after immunization with an islet allograft or OVA ( Figure 1A ). This was not increased by gating on Th1 (IFN-γ + ) or Th2 (IL-4 + or IL-10 + ) CD4 + T cells induced by these stimuli (Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI46274DS1). Similarly, TIM-1 expression on Foxp3 + Tregs and on CD11c + or CD11b + leukocytes was minimal (Supplemental Figure 1, A and B) . In contrast, we found that in naive mice, 5%-8% of splenic B cells constitutively expressed TIM-1, and this increased to 10%-15% after immunization with an allograft or OVA ( Figure 1A ). The same level of TIM-1 expression on B cells was observed using 3 different previously described (4, 7, 9, 27) anti-TIM-1 mAbs ( Figure 1B) . Finally, levels of TIM-1 surface expression, as detected by flow cytometry, correlated with protein expression, determined by Western blotting of sort-purified T cells, B cells, and TIM-1 + and TIM-1 -B cells ( Figure 1C) .
B lymphocytes are required for prolonged allograft survival induced by anti-TIM-1. Based on high levels of expression, we addressed the role of TIM-1 on B cells. Chemically diabetic BALB/c recipients of C57BL/6 (B6) islet allografts were untreated or treated with anti-TIM-1 mAb RMT1-10, which we previously showed to inhibit EAE and prolong cardiac allograft survival (7, 9) . In untreated WT mice or those treated with isotype control mAb, islet rejection occurred with a median survival time (MST) of 13 days (Figure 2A ). Treat- ment with 3 doses of anti-TIM-1 significantly prolonged islet allograft survival (MST, 28 days), with approximately 30% of mice achieving long-term engraftment (>100 days). Depletion of B cells in recipients prior to transplantation using anti-CD20 slightly shortened allograft survival compared with B cell-intact mice (MST, 10 days). Surprisingly, rather than prolonging allograft survival, anti-TIM-1 treatment significantly accelerated allograft rejection in B cell-depleted recipients (MST, 6 days). This was confirmed in chemically diabetic B cell-deficient JHD (BALB/c) recipients of B6 islets. Untreated JHD recipients, or those treated with isotype control mAb, rejected islet allografts with a MST of 12-14 days ( Figure 2B ). As in B cell-depleted WT recipients, JHD mice treated with anti-TIM-1 exhibit a 2-fold acceleration in rate of acute rejection (MST, 7 days). Reconstitution of JHD mice with 10 7 WT B cells, followed by anti-TIM-1 treatment, significantly enhanced allograft survival (MST, 42 days). Thus, not only were B cells required for enhanced allograft survival by anti-TIM-1, but in their absence, this mAb paradoxically shortened survival. This reveals a key role for B cells in TIM-1-mediated tolerance.
B cells are required for Th2 cytokine expression induced by anti-TIM-1. Previously, we showed that RMT1-10 augmented Th2 responses and that this was required for prolonged cardiac allograft survival (9) . Similarly, in islet allograft recipients, anti-TIM-1 inhibited IFN-γ expression and augmented IL-4 and IL-10 expression by CD4 + T cells ( B lymphocytes are required for anti-TIM-1-mediated prolongation of allograft survival. (A) Chemically diabetic BALB/c mice were untreated or subjected to B cell depletion with anti-CD20 (250 μg i.v. on days -14 and -1) followed by transplantation with B6 islets. Allograft recipients were either untreated or treated with RMT1-10 or control Ig at 0.5 mg (day -1) and 0.3 mg (days 0 and 5). (B) JHD mice were unmanipulated or received 10 7 WT syngeneic B cells followed by transplantation with B6 islets (day 0). Allograft recipients were treated as in A. Shown are Kaplan-Meir plots of graft survival. *P < 0.05, **P < 0.01 vs. untreated or control Ig; # P < 0.05 vs. other anti-CD20 groups; † P < 0.01 vs. B cells.
anti-TIM-1 mAb 3B3, which promotes rejection and a Th1 response (7, 8) , did not augment either TIM-1 or expression of IL-4 or IL-10 by B cells (data not shown). Taken together, these observations suggest that anti-TIM-1 (specifically RMT1-10) induces a subset of TIM-1 + IL-10 + B cells with potential regulatory activity.
To determine whether anti-TIM-1 can induce TIM-1 expression de novo, sort-purified TIM-1 -B cells were transferred into naive or transplanted JHD mice with or without anti-TIM-1 treatment. In the absence of an allograft, transferred TIM-1 -B cells remained essentially TIM-1 -, regardless of whether mice received anti-TIM-1 ( Figure 4F ). In the presence of an alloantigen (with or without control Ig), approximately 2% of TIM-1 -B cells expressed TIM-1. However, treatment of allograft recipients with anti-TIM-1 induced TIM-1 expression on approximately 20% of B cells that were originally TIM-1 -. Similar findings were obtained when JHD mice were exposed to alloantigen as i.p. splenocytes (2 × 10 7 ; mitomycin C-treated) rather than an allograft (data not shown).
In this setting, anti-TIM-1 could act directly on the small per- (Supplemental Figure 2A) . Indeed, after adoptive transfer into anti-TIM-1-treated JHD allograft recipients, over 23% of WT B cells expressed TIM-1 and greater than 6% expressed IL-10, whereas only 6% of Il4 -/-B cells expressed TIM-1 and 3% expressed IL-10 ( Figure  5 , B and C). The defects in TIM-1 and IL-10 expression were even more severe in B cells from Il4ra -/-mice. After adoptive transfer into treated JHD recipients, only 3% of Il4ra -/-B cells expressed TIM-1, and 1.3% expressed IL-10 ( Figure 5 , B and C). Concordantly, Il4ra -/-B cells were unable to protect JHD recipients from accelerated rejection after anti-TIM-1 treatment, as seen in mice lacking B cells altogether ( Figure 2 and Figure 5A ). Thus, prolongation of anti-TIM-1-mediated graft survival by B cells correlates directly with TIM-1 and IL-10 expression. Moreover, normal TIM-1 and IL-10 expression on B cells is critically dependent on IL-4 signaling.
As shown in Figure 5B , TIM-1 expression remained low on Il4 -/-B cells transferred into anti-TIM-1-treated JHD allograft recipi- Figure 2B) .
To further confirm the role of IL-4 signaling on TIM-1 induction, sort-purified TIM-1 -B cells from WT, Il4 -/-, and Il4ra -/-mice were stimulated in vitro for 48 hours in the presence or absence of exogenous IL-4. TIM-1 expression was readily induced on WT Figure 2D) . In contrast, TIM-1 induction by anti-IgM was markedly reduced in Il4 -/-(TIM-1 -) B cells (Supplemental Figure 2C) . However, when exogenous IL-4 was added, TIM-1 expression by Il4 -/-and WT B cells was comparable. Thus, Il4 -/-B cells are capable of TIM-1 induction if IL-4 signaling occurs. In contrast, Il4ra -/-B cells had defective TIM-1 induction after anti-IgM, and, as expected, this was not restored by exogenous IL-4. These results correlated closely with the in vivo effects of B cells from Il4 -/-and Il4ra -/-mice ( Figure 5) ; together, these findings indicate that induction of TIM-1 expression requires BCR and IL-4 signaling.
TIM-1 + B cells are regulatory and transfer donor-specific long-term graft survival. Next, TIM-1
+ B cells were directly tested for regulatory activity. BALB/c allograft recipients treated with anti-TIM-1 were sacrificed on day 14. Splenic B cells from these mice were sorted into TIM-1 + and TIM-1 -populations and transferred into otherwise untreated JHD recipients of B6 islets. Whereas transfer of TIM-1 -B cells had no effect (MST, 15 days), transfer of TIM-1 + B cells markedly prolonged allograft survival, with 50% surviving longterm ( Figure 6A ). In contrast, TIM-1 + B cells obtained from Il10 -/-islet allograft recipients were defective in their regulatory capacity (MST, 22 days) compared with WT TIM-1 + B cells. Similarly, TIM-1 + B cells from Il4ra -/-allograft recipients lacked regulatory activity, consistent with their significantly reduced IL-10 expression.
Next, we addressed whether TIM-1 + B cells present in the absence of TIM-1 ligation (which augments TIM-1, IL-10, and IL-4 expression) are also regulatory. Adoptive transfer of TIM-1 + B cells from untreated BALB/c recipients of a B6 allograft were able to markedly prolong graft survival in JHD recipients of B6 islets ( Figure 6B ). In contrast, TIM-1 + B cells obtained from naive (untransplanted) mice were unable to prolong allograft survival when transferred into JHD recipients. These data were consistent with previous reports indicating that Bregs must be activated to be effective (19) . Moreover, consistent with other Bregs (15, 16, 30, 31) , TIM-1 + Bregs were antigen specific, since TIM-1 + B cells from mice receiving an unrelated (C3H) allograft were unable to prolong graft survival when transferred into JHD recipients of B6 islets ( Figure 6B) . Likewise, transfer of TIM-1 + B cells from BALB/c mice exposed to B6 alloantigen protected JHD recipients from rejecting B6 islets, but not C3H islets (Supplemental Figure 3A) . When JHD mice received both B6 and C3H islets (right and left kidney capsules, respectively), acute rejection did not occur. However, histological assessment of allografts revealed heavy CD3 + infiltration of C3H grafts on day 14 (data not shown) and complete disappearance by day 25, whereas B6 allografts were preserved (Supplemental Figure  3B ). This demonstrated that activation of antigen-specific Bregs was insufficient to prevent an immune response against a different antigen in the same host. Thus, TIM-1 + B cells exhibited potent antigen-specific regulatory function and were capable of augmenting IL-4 and IL-10 expression while inhibiting IFN-γ expression by endogenous CD4 + T cells ( Figure 6C ). Transferred TIM-1 + Bregs also augmented the frequency of Foxp3 + Tregs.
Bregs have previously been implicated in amelioration of allergic airway disease (31) (32) (33) . Adoptive transfer of TIM-1 + , but not TIM-1 -, B cells from mice with OVA-induced local inhalational tolerance, markedly reduced OVA-induced allergic airway disease in JHD recipients, as determined by reduced BAL leukocytosis, tissue inflammation, and bronchiolar goblet cell hyperplasia (Supplemental Figure 4) , thus confirming our results in an independent model.
TIM-1 identifies the majority of IL-10 + Bregs and encompasses other IL-10-expressing Breg populations. Bregs, defined by their functional capacity
and ability to produce IL-10, have been reported as low-frequency cells belonging to various B cell subpopulations. Recently, it was suggested that a novel subset of B cells expressing a CD1d hi CD5 + phenotype might account for most IL-10 + Bregs in spleen (15, 19, 34) . Although enriched for IL-10 expression (~18%), this population made up only about 2% of splenic B cells (ref. 15 and Figure  7A ). Here, within the predominant (98%) non-CD1d hi CD5 + population, 1.0%-1.5% of B cells also expressed IL-10. When relative number was taken into account, calculations suggested that less that 25% of all IL-10 + B cells should express the CD1d hi CD5 + phenotype. To directly test this, we used multicolor flow cytometry to first gate on CD19 + IL-10 + splenic B cells. Only 22% ± 4.5% (SD) of these cells fell within the CD1d hi CD5 + gate ( Figure 7B ). In marked contrast, 71% ± 5.3% of all IL-10 + B cells were TIM-1 + .
Given that most IL-10 + B cells in spleen express TIM-1, we asked whether this marker could further identify IL-10-expressing cells within other B cell subpopulations previously shown to contain Bregs. Within the CD1d hi CD5 + B cell population discussed above, TIM-1 + cells were even more highly enriched for IL-10 (33%). In contrast, TIM-1 -cells within the CD1d hi CD5 + subset exhibited an approximate 8-fold decrease in frequency of IL-10 expression (Figure 7, A and D) .
Although uncommon, IL-10 + cells within the non-CD1d hi CD5 + population represented a numerical majority of IL-10-expressing B cells in spleen (see above). Unfortunately, to our knowledge there has been no consistent marker allowing identification of rare IL-10 + cells within this vast B cell population. Here, we found that TIM-1 was present on 8% of non-CD1d hi CD5 + B cells, and in this population, TIM-1 + B cells were enriched greater than 15-fold for IL-10 expression compared with their TIM-1 -counterparts ( Figure  7A ). Similar findings were observed using IL-10 reporter mice (B6 background; Supplemental Figure 5A ), confirming these findings in a second strain. Moreover, after TIM-1 ligation, TIM-1 expression was increased, reaching 45% of CD1d hi CD5 + B cells, of which approximately 45% expressed IL-10 ( Figure 7C and Supplemental Figure 5B ). After TIM-1 ligation, TIM-1 expression on nonCD1d hi CD5 + B cells increased to 15%, of which approximately 10% expressed IL-10. Thus, TIM-1 identified most IL-10 + B cells within the CD1d hi CD5 + subset and also identified a large number of IL-10 + B cells excluded by the CD1d hi CD5 + phenotype.
We also examined the distribution of TIM-1 on more typical splenic B cell subsets in naive mice (35) Discussion TIM-1 has previously been identified as a T cell costimulatory molecule that regulates both auto- and alloimmunity through its effects on CD4 + effector responses (1) . We now show, for the first time to our knowledge, that TIM-1 not only broadly identifies Bregs, but plays an important functional role on B cells that is critical for anti-TIM-1-mediated tolerance. TIM-1 ligation with the lowaffinity anti-TIM-1 mAb RMT1-10, that normally promotes a Th2 response and prolongs allograft survival, paradoxically induced a Th1 response and accelerated rejection in the absence of B cells. TIM-1 ligation on B cells enhanced their IL-4 and IL-10 expression, and both were required for Th2 responses in the allograft setting ( Figure 3A , Figure 5D , and data not shown). Although very few B cells expressed IL-4, we demonstrated that these were greatly enriched in the fraction bearing TIM-1. Of note, overexpression of TIM-1 in T cells augments IL-4 transcription (36), and a similar signaling pathway could operate in B cells. In addition to promoting Th2 deviation, TIM-1 ligation also enhances IL-10 expression on Tregs in a B cell-dependent manner. Both Tregs and Th2 cytokines are required for prolonged allograft survival mediated by anti-TIM-1 (9) . However, these data do not preclude the possibility that anti-TIM-1 has important effects on T cells that either are independent or amplify the effects on B cells.
It is now recognized that Bregs promote tolerance in a number of autoimmune models, including EAE, inflammatory bowel disease, collagen-induced arthritis, allergic airway disease, and diabetes mellitus (15, 17-21, 30, 31, 37) . Lacking a specific marker, such Breg activity appears to reside within uncommon IL-10-expressing B cells scattered within various B cell subpopulations. Moreover, IL-10 production by B cells capable of regulatory activity does not occur in situ, but can be detected only after brief stimulation ex vivo (10) . Even then, only 1%-2% of all B cells in spleen, and even less in LN or bone marrow, are IL-10 competent (10). These factors have complicated the identification and study of Bregs.
The recent identification of CD1d hi CD5 + B cells, which express IL-10 with relatively high frequency, was an important step forward. This subset was thought to identify most IL-10-producing Bregs, including many previously attributed to the MZ or T2-MZ subsets (10, 15) . Although strongly enriched for IL-10 expression, the CD1d hi CD5 + population is very small and actually accounts for less than 25% of all IL-10 + B cells in spleen. An approach for identifying infrequent IL-10 + cells scattered within other or larger B cell subpopulations has been lacking. We showed here that within multiple B cell subpopulations,TIM-1 + B cells were enriched 8- to 20-fold for IL-10 expression compared with their TIM-1 -counterparts. Indeed, when splenic B cells were first gated on IL-10 expression, TIM-1 encompassed more than 70% of the IL-10 + population. Thus, TIM-1 not only markedly enhanced identification of IL-10-expressing B cells within the CD1d hi CD5 + and MZ populations, but also substantially enriched for IL-10 + B cells within the large FO B cell population (~40% of splenic B cells). Moreover, unlike other markers (19) , TIM-1 also identified IL-10 + B cells in LNs and peritoneal cavity. For example, in naive mice, TIM-1 identified 3%-5% of LN B cells, and these were 6-fold enriched for IL-10 expression compared with TIM-1 -cells (Supplemental Figure 5C ). TIM-1 also identified approximately 15% of peritoneal B1-b and B1-a cells, of which 18%-25% expressed IL-10 ( Supplemental Figure 5D ). We therefore believe that TIM-1 represents the broadest and most specific marker for Bregs identified thus far.
The finding that TIM-1 ligation on B cells induced TIM-1 + B cells with regulatory activity indicates that TIM-1 signaling is involved in this process. Thus far, anti-TIM-1 appears unique in its ability to induce Bregs across a wide spectrum of phenotypes. In comparison, BAFF and anti-CD40 are reported to induce Bregs specifically within the splenic MZ and T2 populations, respectively (38, 39) . Moreover, both of these agents exhibit dual agonist and antagonist functions, raising the concern that they may not uniformly inhibit the immune response in all disease settings.
In addition to increasing the number of TIM-1 + B cells, anti-TIM-1 also augmented their ability to express immunomodulatory cytokines. Thus, TIM-1 ligation in allograft recipients resulted in TIM-1 expression in 35%-40% of CD1d hi CD5 + B cells as well as in the MZ and B1 populations, and IL-10 was expressed by 35%-45% of these cells. Even within the major FO B cell population, anti-TIM-1 treatment increased TIM-1 and IL-10 expression, resulting in a 3-fold increase in number of IL-10 + cells. Since TIM-1 identifies IL-10 + cells within each B cell subset, it may allow the relative regulatory activity and lineal relationship between such cells to be studied.
The current study also provides what we believe to be new insight into signals involved in Breg generation (Figure 8 In agreement with previous studies, IL-10 played a critical role in Breg activity. Neither TIM-1 + Il10 -/-nor Il4ra -/-B cells (defective in IL-10 expression) could transfer tolerance to otherwise-untreated allograft recipients. However, Il10 -/-B cells modestly prolonged allograft survival in anti-TIM-1-treated B cell-deficient recipients, which suggested that in this setting, additional regulatory mechanisms may play a role.
TIM-1 plays an important role in regulating the immune response. We showed here that many of the effects on T cells resulting from TIM-1 ligation with a low-affinity mAb were actually B cell dependent. TIM-1 represented an inclusive marker for Bregs highly enriched for IL-10 expression in spleen and LN of both naive mice and those undergoing active immune responses. Transfer of TIM-1 + , but not TIM-1 -, B cells after antigen challenge markedly prolonged survival of fully MHC-mismatched allografts in otherwise-untreated recipients. To our knowledge, RMT1-10 is the first agent to selectively induce Bregs in vivo and the first tolerogenic agent to promote allograft tolerance through Bregs. These findings may represent a fresh therapeutic approach and provide insight into the signals involved in the generation and induction of Bregs.
